Diagnosis and treatment of breast cancer in young women

L Rossi, C Mazzara, O Pagani - Current treatment options in oncology, 2019 - Springer
Opinion statement Despite the increase of breast cancer incidence with age, approximately
7 to 10% ofwomen diagnosed with breast cancer are younger than the age 40. This …

Psychological impact of alterations in sexuality, fertility, and body image in young breast cancer patients and their partners

M Miaja, A Platas… - Revista de investigacion …, 2017 - medigraphic.com
Young women with breast cancer have age-specific concerns regarding changes in
sexuality, fertility, and body image. However, the psychological impact of BC and its …

Fertility preservation in patients with cancer: ASCO clinical practice guideline update

K Oktay, BE Harvey, AH Partridge, GP Quinn… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To provide current recommendations about fertility preservation for adults and
children with cancer. Methods A systematic review of the literature published from January …

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

D Tripathy, SA Im, M Colleoni, F Franke… - The lancet …, 2018 - thelancet.com
Background In MONALEESA-2, ribociclib plus letrozole showed improved progression-free
survival compared with letrozole alone as first-line treatment for postmenopausal patients …

[HTML][HTML] ESO–ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)

S Paluch-Shimon, F Cardoso, AH Partridge… - Annals of …, 2020 - Elsevier
Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)

S Paluch-Shimon, O Pagani, AH Partridge, O Abulkhair… - The Breast, 2017 - Elsevier
Abstract The 3rd International Consensus Conference for Breast Cancer in Young Women
(BCY3) took place in November 2016, in Lugano, Switzerland organized by the European …

[HTML][HTML] ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

S Paluch-Shimon, F Cardoso, AH Partridge… - Annals of …, 2022 - Elsevier
Highlights•Breast cancer in young women encompasses unique treatment and survivorship
considerations.•Fertility, ovarian function suppression and premature menopause are major …

Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial

HA Kim, JW Lee, SJ Nam, BW Park, SA Im… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The addition of ovarian function suppression (OFS) for 5 years to tamoxifen
(TAM) for treatment of premenopausal patients with breast cancer after completion of …

Fertility preservation using GnRH agonists: rationale, possible mechanisms, and explanation of controversy

Z Blumenfeld - Clinical Medicine Insights: Reproductive …, 2019 - journals.sagepub.com
The only clinically accepted method of fertility preservation in young women facing
gonadotoxic chemo-and/or radiotherapy for malignant or autoimmune diseases is …

[HTML][HTML] Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence …

M Lambertini, M Cinquini, I Moschetti… - European Journal of …, 2017 - Elsevier
The development of premature ovarian failure and subsequent infertility are possible
consequences of chemotherapy use in pre-menopausal women with early-stage breast …